Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × Fluorouracil × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 11 Rectal Neoplasms 6 Pancreatic Neoplasms 6 Nasopharyngeal Carcinoma 5 Colonic Neoplasms 4 Cholangiocarcinoma 4 Stomach Neoplasms 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Neoplasm Metastasis 2 Keratosis, Actinic 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Biliary Tract Neoplasms 2 Appendiceal Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Resectable Colon Cancer 1 Rare Tumour 1 Pathologic Complete Response 1 Pancreatic Cancer Resectable 1 PDAC - Pancreatic Ductal Adenocarcinoma 1 Neoplasms, Second Primary 1 Neoplasms 1 Neoplasm, Residual 1 Neoadjuvant Chemotherapy 1 Muscle Neoplasms 1 Locally Advanced Low Rectal Adenocarcinoma 1 Liver Neoplasms 1 Liver Metastases of Colorectal Cancer 1 Laryngeal Diseases 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡